Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy
Phase 2 study shows high response rates in BTKi-naive R/R MCL, indicating brexu-cel's potential for earlier treatment.
Key Points
This research evaluates the safety and efficacy of brexu-cel in patients with relapsed/refractory mantle cell lymphoma who are naive to Bruton tyrosine kinase inhibitors.
Phase 2 study involving patients with R/R MCL who underwent leukapheresis, lymphodepleting chemotherapy, and brexu-cel infusion.
Primary endpoint was the objective response rate (ORR) assessed by independent radiology review.
Secondary endpoints included complete response rates, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety analyses.
The ORR was 91% with a complete response rate of 79% after a median follow-up of 26.4 months.
Median DOR and PFS were not reached, with ongoing response rates consistently high across key subgroups.
The rate of adverse events increased slightly, with late onset toxicities remaining rare.